Valvular Abnormalities and Cardiovascular Status Following Exposure to Dexfenfluramine or Phentermine/Fenfluramine

Abstract
Dexfenfluramine and fenfluramine are antiobesity agents that were indicated as adjunctive therapies to a weight loss regimen that included dietary restriction.1,2 Dexfenfluramine had been available in Europe since 1985 but was on the US market for less than 16 months. Fenfluramine was available both domestically and abroad for more than 20 years. Reports of valvular abnormalities in 1997 resulted in the voluntary withdrawals of these agents from the market. However, these observational reports lacked pretreatment echocardiographic data and nonanorexigen-treated control cohorts, and criteria for subject selection were unclear.

This publication has 12 references indexed in Scilit: